The essential role of the hyperactivated EGFR-KRAS-BRAF signaling cascade in CRC has spurred the development of therapeutic approaches to inhibit the cascade on several levels, specifically targeting EGFR, KRAS and BRAF (Fig. 3, Table 1). The gene discussed is KRAS; the disease is colorectal carcinoma.